Pang XC - Search Results

1

Frizzled receptors (FZDs) in Wnt signaling: potential therapeutic targets for human cancers.

Liu HY, Sun XJ, Xiu SY, Zhang XY, Wang ZQ, Gu YL, Yi CX, Liu JY, Dai YS, Yuan X, Liao HP, Liu ZM, Pang XC, Li TC. Liu HY, et al. Among authors: pang xc. Acta Pharmacol Sin. 2024 Apr 17. doi: 10.1038/s41401-024-01270-3. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 38632318 Review.

2

The challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials.

Gu Y, Dong B, He X, Qiu Z, Zhang J, Zhang M, Liu H, Pang X, Cui Y. Gu Y, et al. Pharmacol Res. 2023 Mar;189:106694. doi: 10.1016/j.phrs.2023.106694. Epub 2023 Feb 10. Pharmacol Res. 2023. PMID: 36775082 Free article. Review.

3

Identification of potential ferroptosis-associated biomarkers in rheumatoid arthritis.

He X, Zhang J, Gong M, Gu Y, Dong B, Pang X, Zhang C, Cui Y. He X, et al. Front Immunol. 2023 Jul 10;14:1197275. doi: 10.3389/fimmu.2023.1197275. eCollection 2023. Front Immunol. 2023. PMID: 37492576 Free PMC article.

4

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.

Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, Cui Y. Xiang Q, et al. Pharmacol Ther. 2019 Nov;203:107393. doi: 10.1016/j.pharmthera.2019.107393. Epub 2019 Jul 26. Pharmacol Ther. 2019. PMID: 31356909 Free article. Review.

5

Targeting integrin pathways: mechanisms and advances in therapy.

Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q, Cui Y. Pang X, et al. Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6. Signal Transduct Target Ther. 2023. PMID: 36588107 Free PMC article. Review.

6

IUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities.

He X, Wedn A, Wang J, Gu Y, Liu H, Zhang J, Lin Z, Zhou R, Pang X, Cui Y. He X, et al. Pharmacol Res. 2024 Mar;201:107063. doi: 10.1016/j.phrs.2024.107063. Epub 2024 Jan 11. Pharmacol Res. 2024. PMID: 38216006 Free article. Review.

7

Platelet factor 4(PF4) and its multiple roles in diseases.

Liu Z, Li L, Zhang H, Pang X, Qiu Z, Xiang Q, Cui Y. Liu Z, et al. Blood Rev. 2024 Mar;64:101155. doi: 10.1016/j.blre.2023.101155. Epub 2023 Nov 23. Blood Rev. 2024. PMID: 38008700 Review.

8

Osteopontin as a multifaceted driver of bone metastasis and drug resistance.

Pang X, Gong K, Zhang X, Wu S, Cui Y, Qian BZ. Pang X, et al. Pharmacol Res. 2019 Jun;144:235-244. doi: 10.1016/j.phrs.2019.04.030. Epub 2019 Apr 24. Pharmacol Res. 2019. PMID: 31028902 Free article. Review.

9

Corrigendum to "DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice" [Pharmacol. Biochem. Beha. Volume 139, Part A, December 2015, Pages 15-26].

Yang RY, Zhao G, Wang DM, Pang XC, Wang SB, Fang JS, Li C, Liu AL, Wu S, Du GH. Yang RY, et al. Among authors: pang xc. Pharmacol Biochem Behav. 2024 Jun;239:173758. doi: 10.1016/j.pbb.2024.173758. Epub 2024 Apr 18. Pharmacol Biochem Behav. 2024. PMID: 38640515 No abstract available.

10

Macrophages promote anti-androgen resistance in prostate cancer bone disease.

Li XF, Selli C, Zhou HL, Cao J, Wu S, Ma RY, Lu Y, Zhang CB, Xun B, Lam AD, Pang XC, Fernando A, Zhang Z, Unciti-Broceta A, Carragher NO, Ramachandran P, Henderson NC, Sun LL, Hu HY, Li GB, Sawyers C, Qian BZ. Li XF, et al. Among authors: pang xc. J Exp Med. 2023 Apr 3;220(4):e20221007. doi: 10.1084/jem.20221007. Epub 2023 Feb 7. J Exp Med. 2023. PMID: 36749798 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page